-
Posted: March 10th, 2010, 7:00pm CST
It's long been known that obesity is linked to increased risk of developing colon cancer, but now researchers at the Mayo Clinic campus in Minnesota have found that obesity is associated with worse outcomes in patients who have already been diagnosed and treated for the cancer...
-
Posted: March 10th, 2010, 11:00am CST
Scientists in the US who undertook a large study to investigate what biological mechanisms might be behind the already established link between colorectal cancer and consumption of red and processed meat, confirmed that such a link exists and suggested the main players are three compounds: heme iron, nitrate/nitrite, and heterocyclic amines...
-
Posted: March 10th, 2010, 10:00am CST
Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year...
-
Posted: March 10th, 2010, 7:00am CST
A Princeton University-led research team has discovered that protein competition over an important enzyme provides a mechanism to integrate different signals that direct early embryonic development. The work suggests that these signals are combined long before they interact with the organism's DNA, as was previously believed, and also may inform new therapeutic strategies to fight cancer...
-
Posted: March 10th, 2010, 6:00am CST
Individuals with a certain type of genetic susceptibility to lung cancer face a greatly increased risk for the deadly disease with even a small exposure to cigarette smoke, a study team that includes researchers from the University of Cincinnati (UC) has concluded...
-
Posted: March 10th, 2010, 4:00am CST
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year...
-
Posted: March 10th, 2010, 4:00am CST
The humble papaya is gaining credibility in Western medicine for anticancer powers that folk cultures have recognized for generations. University of Florida researcher Nam Dang, M.D., Ph.D., and colleagues in Japan have documented papaya's dramatic anticancer effect against a broad range of lab-grown tumors, including cancers of the cervix, breast, liver, lung and pancreas...
-
Posted: March 10th, 2010, 3:00am CST
What began as research into how diabetics could possibly preserve their eyesight has led to findings that could prolong the vision of children afflicted with retinoblastoma...
-
Posted: March 10th, 2010, 3:00am CST
The interaction of a ligand (Neurotrophine-3) and its dependence receptor (TrkC) constitutes a novel mechanism for tumor control in pediatric cancers such as neuroblastoma, and may also be important to the inhibition of other cancers such as breast cancer...
-
Posted: March 10th, 2010, 3:00am CST
Changes in patients' self-rated quality of life after treatment for esophago-gastric cancer can predict the chances for long-term survival. This is the result researchers at the Swedish medical university Karolinska Institutet made, in a new study published in the Journal of Clinical Oncology. The patient's self-rated quality of life, provide indications of whether he or she will survive...
-
Posted: March 10th, 2010, 3:00am CST
For the first time, scientists have succeeded in growing empty particles derived from a plant virus and have made them carry useful chemicals. The external surface of these nano containers could be decorated with molecules that guide them to where they are needed in the body, before the chemical load is discharged to exert its effect on diseased cells...
-
Posted: March 10th, 2010, 2:00am CST
mtm laboratories, a privately held diagnostics company announced the launch of CINtec® PLUS, the company's next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer...
-
Posted: March 10th, 2010, 1:00am CST
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®...
-
Posted: March 10th, 2010, 12:00am CST
Argos Therapeutics announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium...